Lake Street raised the firm’s price target on Sight Sciences (SGHT) to $7 from $5 and keeps a Buy rating on the shares after two Medicare administrative contractors finalized coverage policies for Sight Sciences’ Dry Eye Disease treatment system, TearCare. The firm sees this as “a significant positive that could be a driver of outperformance,” the analyst tells investors.
Meet Your ETF AI Analyst
- Discover how TipRanks' ETF AI Analyst can help you make smarter investment decisions
- Explore ETFs TipRanks' users love and see what insights the ETF AI Analyst reveals about the ones you follow.
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on SGHT:
- Sight Sciences Gains Medicare Pricing for TearCare
- Sight Sciences announces fee schedule establishment for TearCare procedure
- Sight Sciences to provide updated revenue guidance on Q3 earnings call
- Sight Sciences price target lowered to $4 from $4.50 at Citi
- Sight Sciences Amends Loan Agreement with Hercules